In a 48-week placebo-controlled trial, 398 patients 12 to 17 years of age with moderate asthma were randomly assigned to receive tiotropium 5 μg, tiotropium 2.5 μg, or an identical placebo delivered ...

The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the ...

Am J Health Syst Pharm. 2005;62(12):1263-1269. Tiotropium is well tolerated, with dry mouth as the most commonly reported adverse effect. Its low potential for adverse effects, ease of administration, ...

LONDON & INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma ® trial that showed adding tiotropium Respimat ® to maintenance ...

Phase III studies show once-daily Onbrez Breezhaler plus tiotropium improved lung function (measured by trough FEV1) by up to 230 mL from baseline[1] Reported incidence of side effects was similar in ...

Please provide your email address to receive an email when new articles are posted on . Daily tiotropium via the HandiHaler device improved lung function but did not reduce frequency of exacerbations ...

SAN ANTONIO, Texas--(BUSINESS WIRE)--Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite ...

Since its registration in 2002, a dry-powder formulation of tiotropium delivered by a HandiHaler inhalation device has consistently been recommended in clinical-practice guidelines as first-line ...

New research suggests that tiotropium, a long-acting anticholinergic used in patients with COPD, may be associated with a reduction in all-cause mortality, cardiovascular mortality, and cardiovascular ...

COPD patients taking the long-acting antimuscarinic tiotropium are 30% less likely to be hospitalised compared with those taking long-acting beta agonists, say researchers. The results of the first ...

Novartis International AG / Novartis studies show Onbrez® Breezhaler® plus tiotropium is more effective than tiotropium alone in treatment of COPD . Processed and transmitted by Thomson Reuters ONE.